Neuland Laboratories Ltd vs Sandu Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Neuland Laboratories Ltd is ₹ 14998 as of 30 Apr 15:30 . The P/E Ratio of Neuland Laboratories Ltd changed from 33.4 on March 2021 to 59.9 on March 2025 . This represents a CAGR of 12.39% over 5 yearsThe P/E Ratio of Sandu Pharmaceuticals Ltd changed from 33.3 on March 2023 to 30.4 on March 2025 . This represents a CAGR of -2.99% over 3 years The Market Cap of Neuland Laboratories Ltd changed from ₹ 2678 crore on March 2021 to ₹ 15494 crore on March 2025 . This represents a CAGR of 42.05% over 5 yearsThe Market Cap of Sandu Pharmaceuticals Ltd changed from ₹ 50.43 crore on March 2023 to ₹ 47.33 crore on March 2025 . This represents a CAGR of -2.09% over 3 years The revenue of Neuland Laboratories Ltd for the Dec '25 is ₹ 447.76 crore as compare to the Sep '25 revenue of ₹ 516.07 crore. This represent the decline of -13.24% The revenue of Sandu Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Neuland Laboratories Ltd for the Dec '25 is ₹ 85.19 crore as compare to the Sep '25 ebitda of ₹ 157.35 crore. This represent the decline of -45.86% The ebitda of Sandu Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Neuland Laboratories Ltd changed from ₹ 97.87 crore to ₹ 40.57 crore over 7 quarters. This represents a CAGR of -39.54% The net profit of Sandu Pharmaceuticals Ltd changed from ₹ 0.17 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The Dividend Payout of Neuland Laboratories Ltd changed from 8.03 % on March 2021 to 5.97 % on March 2025 . This represents a CAGR of -5.76% over 5 yearsThe Dividend Payout of Sandu Pharmaceuticals Ltd changed from 36.33 % on March 2021 to 49.86 % on March 2025 . This represents a CAGR of 6.54% over 5 years .

About Neuland Laboratories Ltd

Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao.
The Company is engaged in manufacturing and selling of bulk drugs such as Salbutamol Sulphate, Terbutaline Sulphate, Labetalol Hydrochloride and Ciprofloxacin.
Neuland Drugs & Pharmaceuticals Pvt.
Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992.
NLL manufactures bulk drugs. The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix.

About Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd (SPL) was established in 1985.
The Company is mainly engaged in the business of manufacturing and trading of Ayurvedic medicines under the brand name SANDU. SPL came out with a public issue of 17.70 lac equity shares at par, aggregating Rs 1.77 cr, in Sep.'94, to part-finance its new project in Goa costing Rs 7.28 cr to manufacture ayurvedic medicines and formulations.
This plant employs the latest material handling systems and other modern machinery and has the most hygienic production facilities to attain the highest possible quality standards.
Ayurvedic products have a very good market in India and abroad due to their minimal side effects. The company commenced commercial production of Ayurvedic Medicines & Formulations, at the Goa plant in 1996-97.
Thereafter, it commenced production of manufacturing Unit II in Goa from May, 2002.

FAQs for the comparison of Neuland Laboratories Ltd and Sandu Pharmaceuticals Ltd

Which company has a larger market capitalization, Neuland Laboratories Ltd or Sandu Pharmaceuticals Ltd?

Market cap of Neuland Laboratories Ltd is 19,243 Cr while Market cap of Sandu Pharmaceuticals Ltd is 42 Cr

What are the key factors driving the stock performance of Neuland Laboratories Ltd and Sandu Pharmaceuticals Ltd?

The stock performance of Neuland Laboratories Ltd and Sandu Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Neuland Laboratories Ltd and Sandu Pharmaceuticals Ltd?

As of May 3, 2026, the Neuland Laboratories Ltd stock price is INR ₹14998.7. On the other hand, Sandu Pharmaceuticals Ltd stock price is INR ₹44.0.

How do dividend payouts of Neuland Laboratories Ltd and Sandu Pharmaceuticals Ltd compare?

To compare the dividend payouts of Neuland Laboratories Ltd and Sandu Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.